CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects
Estrela, R.C.E.; Santoro, A.B.; Barroso, P.F.; Tuyama, M.; Suarez-Kurtz, G.
Clinical Pharmacology and Therapeutics 84(2): 205-207
2008
ISSN/ISBN: 0009-9236 PMID: 18288082 DOI: 10.1038/clpt.2008.12Document Number: 202629
CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)-infected individuals on stable highly active antiretroviral therapy (HAART). This is ascribed to a drug interaction, such that ritonavir by inhibiting CYP3A activity, may occlude the pharmacokinetic consequences of functional polymorphisms in the CYP3A5 gene. In the clinical setting, where lopinavir and ritonavir are always combined, CYP3A5 genotype is of no consequence on the trough plasma concentrations of these drugs.
Document emailed within 0-6 h
Related Documents
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
Murphy, R.A.; Marconi, V.C.; Gandhi, R.T.; Kuritzkes, D.R.; Sunpath, H. 2012: Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa Plos one 7(9): E44793
Musiime, V.; Fillekes, Q.; Kekitiinwa, A.; Kendall, L.; Keishanyu, R.; Namuddu, R.; Young, N.; Opilo, W.; Lallemant, M.; Walker, A.S.; Burger, D.; Gibb, D.M. 2014: The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children Journal of Acquired Immune Deficiency Syndromes 66(2): 148-154
Bartelink, I.H.; Savic, R.M.; Mwesigwa, J.; Achan, J.; Clark, T.; Plenty, A.; Charlebois, E.; Kamya, M.; Young, S.L.; Gandhi, M.; Havlir, D.; Cohan, D.; Aweeka, F. 2014: Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda Journal of Clinical Pharmacology 54(2): 121-132
Colombo, S.; Buclin, T.; Franc, C.; Guignard, N.; Khonkarly, M.; Tarr, P.E.; Rochat, B.; Biollaz, J.ér.ôm.; Telenti, A.; Decosterd, L.A.; Cavassini, M. 2006: Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures Antiviral Therapy 11(1): 53-62
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Luque, A.E.; Cohn, S.E.; Park, J.-G.; Cramer, Y.; Weinberg, A.; Livingston, E.; Klingman, K.L.; Aweeka, F.; Watts, D.H. 2015: Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study Antimicrobial Agents and ChemoTherapy 59(4): 2094-2101
Chrysos, G.; Mikros, S.; Kokkoris, S.; Pastelli, A.; Kontochristopoulos, G. 2007: Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient Journal of Drugs in Dermatology: Jdd 6(7): 742-743
Shihab, H.M.; Lutwama, F.; Piloya, T.; Castelnuovo, B.; Kambugu, A.D.; Colebunders, R. 2009: Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause? Journal of Infection in Developing Countries 3(5): 405-407
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Sunpath, H.; Winternheimer, P.; Cohen, S.; Tennant, I.; Chelin, N.; Gandhi, R.T.; Murphy, R.A. 2014: Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 18(6): 689-693
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385
Nagot, N.; Kankasa, C.; Meda, N.; Hofmeyr, J.; Nikodem, C.; Tumwine, J.K.; Karamagi, C.; Sommerfelt, H.; Neveu, D.; Tylleskär, T.; Van de Perre, P. 2012: Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174 Bmc Infectious Diseases 12: 246
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Cohn, J.S.; McNamara, J.R.; Schaefer, E.J. 1988: Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states Clinical Chemistry 34(12): 2456-2459
Zangerle, R.; Sarcletti, M.; Gallati, H.; Reibnegger, G.; Wachter, H.; Fuchs, D. 1994: Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation Journal of Acquired Immune Deficiency Syndromes 7(11): 1149-1156